109 related articles for article (PubMed ID: 22951783)
1. [Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Popova EV; Boĭko AN; Vasil'ev AV; Davydovskaia MV; Zavalishin IA; Kotov SV; Krotenkova MV; Khachanova NV; Sharanova SN; Shchur SG; Iakushina TI
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5):56-61. PubMed ID: 22951783
[TBL] [Abstract][Full Text] [Related]
2. [The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
Popova EV; Boĭko AN; Davydovskaia MV; Demina TL; Kukel' TM; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):93-6. PubMed ID: 24300821
[TBL] [Abstract][Full Text] [Related]
3. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
[TBL] [Abstract][Full Text] [Related]
4. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
[TBL] [Abstract][Full Text] [Related]
5. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
6. [The results of an open prospective study of β-interferon biosimilars (an Yaroslavl' cohort)].
Kasatkin DS; Spirin NN; Boiko AN; Stepanov IO; Spirina NN; Baranova NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):68-73. PubMed ID: 27070364
[TBL] [Abstract][Full Text] [Related]
7. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
8. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
9. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
[TBL] [Abstract][Full Text] [Related]
12. [Current status of interferon beta-1b in multiple sclerosis therapy].
Hartung HP
Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
14. [Experience of application of Russian biosimilar of interferon beta-1b for treatment of pediatric multiple sclerosis].
Popova EV; Boyko AN; Bykova OV; Nankina IG; Batysheva TT
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):73-75. PubMed ID: 27456908
[TBL] [Abstract][Full Text] [Related]
15. Use of interferon-beta in the treatment of multiple sclerosis.
Derwenskus J; Lublin FD
Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
[No Abstract] [Full Text] [Related]
16. [Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal].
Khabirov FA; Babicheva NN; Khaĭbullin TI; Aver'ianova LA; Granatov EV; Akhmedova GM
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9 Pt 2):113-22. PubMed ID: 23235429
[TBL] [Abstract][Full Text] [Related]
17. [The possibility of the use of several clinical, genetic and MRI characteristics for the prognosis of effects of beta-interferon-1beta treatment in multiple sclerosis].
Boĭko AN; Khachanova NV; Buglak AV; Demina TL; Beliaeva IA; Lashch NV; Serkov SV; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):53-9. PubMed ID: 11195540
[TBL] [Abstract][Full Text] [Related]
18. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
[No Abstract] [Full Text] [Related]
19. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.
Prosperini L; Mancinelli CR; De Giglio L; De Angelis F; Barletta V; Pozzilli C
Mult Scler; 2014 Apr; 20(5):566-76. PubMed ID: 23999607
[TBL] [Abstract][Full Text] [Related]
20. Interferon beta in multiple sclerosis: how much BENEFIT?
Pittock SJ
Lancet; 2007 Aug; 370(9585):363-4. PubMed ID: 17678997
[No Abstract] [Full Text] [Related]
[Next] [New Search]
